Attached files
file | filename |
---|---|
EX-99.1 - INVESTOR PRESENTATION - Bionik Laboratories Corp. | bnkl_investorpresentation.htm |
8-K - CURRENT REPORT - Bionik Laboratories Corp. | form8-kbionik12417.htm |
Bionik Laboratories to Present at Noble Capital Markets’
Thirteenth Annual Investor Conference
- Presentation with video webcast on
Tuesday, January 31st
at 12:00 p.m. ET -
TORONTO and BOSTON – January 24, 2017 –
Bionik
Laboratories Corp. (OTCQX: BNKL) (“Bionik” or
the "Company"), a global pioneering robotics company focused on
providing rehabilitation and mobility solutions to individuals with
neurological disorders, announced today that
Peter
Bloch, Chief Executive Officer and Chairman of the Board
will present at NobleCon13, the Noble Capital Markets’
Thirteenth Annual Investor Conference, on January 31, 2017 at 12:00
p.m. ET in Boca Raton, FL.
During
his presentation, Mr. Bloch will provide a corporate update and
discuss Bionik’s proprietary healthcare robotics platforms
for stroke and assistance that are commercially available as well
as new products under development for both the upper and lower
body.
Mr.
Bloch will also provide an overview of the Company’s
near-term milestones including the launch of its next generation
upper body commercial product line expected in the second quarter
of 2017 and progression towards commercialization of four
development products: InMotion Light, Bionik’s first product
for the home market, InMotion AnkleBot™, for individuals
suffering from problems of walking and gait associated with
neurological disorders, a lower extremity product for gait
assistance for rehabilitation and ARKE™, a lower body exoskeleton
designed to allow paraplegics and other wheelchair bound
individuals to walk and rehabilitate.
A video
webcast of the presentation and a copy of the presentation
materials will be available by accessing Bionik’s
IR
Calendar in the Investors
section of the Company’s website (www.bioniklabs.com),
and will be accessible as part of a complete catalog of
presentations available at Noble Financial websites: www.noblecapitalmarkets.com
or www.nobleconference.com.
The webcast and presentation will be archived on the Company's
website and on the Noble websites for 90 days following the
event.
About Noble Capital Markets, Inc.
Noble Capital Markets, established in 1984, is an equity-research
driven, full-service, investment & merchant banking boutique
focused on the healthcare, media & entertainment, technology
and natural resources sectors. The company has offices in Boca
Raton, New York and Boston. In addition to NobleCon - the annual
multi-sector investor conference and the Media, Finance &
Investor Conference, produced in partnership with the National
Association of Broadcasters (NAB) and held each spring in Las
Vegas, throughout the year Noble hosts numerous
“non-deal” corporate road shows across the United
States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com.
About Bionik Laboratories
Bionik Laboratories (OTCQX:BNKL), is a global, pioneering robotics
company focused on providing rehabilitation and mobility solutions
to individuals with neurological disorders. The Company has a
portfolio of products focused on upper and lower extremity
rehabilitation for stroke and paraplegic patients, including three
products on the market and four products in varying stages of
development. The InMotion Systems - the InMotion ARM™,
InMotion Wrist™, InMotion Hand™ and InMotion
AnkleBot™, are designed to provide intelligent,
patient-adaptive therapy in a manner that has been clinically
verified to maximize neuro-recovery. Bionik is also developing a
lower-body exoskeleton, ARKE™, designed to allow paraplegics
as well as other wheelchair users the ability to rehabilitate
through walking. ARKE is expected to be designed to continually
adapt to a patient’s ability and provide real time feedback
to the physiotherapist.
For
more information, please visit www.bioniklabs.com
and connect with us on Twitter,
LinkedIn and Facebook.
Forward-Looking Statements
Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons and
other rehabilitation products, (ii) a projection of income
(including income/loss), earnings (including earnings/loss) per
share, capital expenditures, dividends, capital structure or other
financial items, (iii) the Company's future financial performance,
(iv) the successful integration of IMT with Bionik and (v) the
assumptions underlying or relating to any statement described in
points (i), (ii), (iii) or (iv) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain additional financing,
the significant length of time and resources associated with the
development of our products and related insufficient cash flows and
resulting illiquidity, the Company's inability to expand the
Company's business, significant government regulation of medical
devices and the healthcare industry, lack of product
diversification, volatility in the price of the Company's raw
materials, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. The Company does not undertake to update these
forward-looking statements.
Bionik Laboratories Corp. Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
(908) 996-0239
jenene@jenenethomascommunications.com
SOURCE: Bionik Laboratories Corp.
###